Evidence map›Paper›PMID 33482896›Full record

ArticleTrials2021

Effectiveness of a pathway-driven eHealth-based integrated care model (PEICM) for community-based hypertension management in China: study protocol for a randomized controlled trial.

Zheyu Wang, Chengling Li, Wencai Huang, Yan Chen, Yuqiong Li, Libin Huang, Mei Zhang, Dan Wu, Li Wang, Huilong Duan and 2 more

Open access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in Trials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Zheyu Wang *College of Biomedical Engineering and Instrument Science, The Ministry of Education Key Laboratory of Biomedical Engineering, Zhejiang University, Hangzhou, 310027, China.
Chengling Li *The First People's Hospital of Yibin, Yibin, China.
Wencai Huang *ZICT Technology Co.,Ltd., Shenzhen, China.
Yan ChenCollege of Biomedical Engineering and Instrument Science, The Ministry of Education Key Laboratory of Biomedical Engineering, Zhejiang University, Hangzhou, 310027, China.
Yuqiong LiThe First People's Hospital of Yibin, Yibin, China.
Libin HuangZICT Technology Co.,Ltd., Shenzhen, China.
Mei ZhangThe First People's Hospital of Yibin, Yibin, China.
Dan WuCollege of Biomedical Engineering and Instrument Science, The Ministry of Education Key Laboratory of Biomedical Engineering, Zhejiang University, Hangzhou, 310027, China.
Li WangZICT Technology Co.,Ltd., Shenzhen, China.
Huilong DuanCollege of Biomedical Engineering and Instrument Science, The Ministry of Education Key Laboratory of Biomedical Engineering, Zhejiang University, Hangzhou, 310027, China.
Jiye AnCollege of Biomedical Engineering and Instrument Science, The Ministry of Education Key Laboratory of Biomedical Engineering, Zhejiang University, Hangzhou, 310027, China.
Ning DengCollege of Biomedical Engineering and Instrument Science, The Ministry of Education Key Laboratory of Biomedical Engineering, Zhejiang University, Hangzhou, 310027, China. zju.dengning@gmail.com.ORCID http://orcid.org/0000-0002-6573-1061
Zhejiang University · CNSecond People’s Hospital of Yibin · CNZhoushan Institute of Calibration for Quality and Technology Supervision · CNMinistry of Education · NZ

Funding

Key Research and Development Program of Ningxia Hui Autonomous of China 2018BFG02009National Key Research and Development Program of China 2017YFB1002301National Key Research and Development Program of China 2017YFC0114105National Key Research and Development Program of China 2018YFC0910503
6 · The paper itself

Abstract

backgroundThe prevalence of hypertension is high and increasing in China in recent years. The treatment and control of hypertension calls for long-term management beyond hospital, which is hard to implement in traditional care settings. Integrated care combined with information technology can promote high-quality healthcare services across the life-course. However, few studies have applied a customized integrated care model in community-based hypertension management in China, catering to the emerging "three-manager" mode. This study aims to identify the effectiveness of a pathway-driven eHealth-based integrated model that implemented as a full-featured telehealth system to facilitate standardized management of hypertension in China.

methodsThe trial has been designed as a 1-year, non-blinded superiority trial with two parallel groups. A total of 402 hypertensive patients who meet the eligibility criteria will be recruited and randomized with a 1:1 allocation. All the participants will receive a mobile device for self-management, which is a part of our telehealth system. Participants in the control group will only use the device for BP measurement and receive regular follow-ups from care providers according to the guidelines. Participants in the intervention group will gain full access to the system and receive intervention based on the proposed model (a well-designed coordinated care pathway consisting of 9 tasks). Outcomes will be measured mainly on three occasions (at inclusion, at 6 months, and at 12 months). The primary outcome is mean change in systolic blood pressure over a 12-month period. Secondary outcomes include changes in diastolic blood pressure, biochemical indexes related to hypertension, lifestyles, self-management adherence, and hypertension awareness, as well as work efficiency of care providers. DISCUSSION: This study aims to investigate whether a pathway-driven eHealth-based integrated care model based on the "three-manager" mode will improve hypertension control in China. Success of the model would help improve the quality of present community-based management procedures and benefit more patients with uncontrolled hypertension.

trial registrationChinese Clinical Trial Registry ChiCTR1900027645 . Registered on November 22, 2019.

Indexed as

Delivery of Health Care, IntegratedHypertensionTelemedicineBlood PressureChinaEquivalence Trials as TopicHumansRandomized Controlled Trials as TopicCommunityHypertension managementIntegrated carePathwayRandomized controlled trialStudy protocolTelehealth

Identifiers

PMID33482896
PMCPMC7820518
OpenAlexW3119138166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.